Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: A randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Walker, Leslie G ^a   Eremin, Jennifer M ^b   Aloysius, Mark M ^d   Vassanasiri, Wichai ^b   Walker, Mary B ^a   El Sheemy, Mohamed ^b,c   Cowley, Ged ^b   Beer, Jeanette ^b   Samphao, Srila ^b   Wiseman, Janice ^b   Jibril, Jibril A ^b   Valerio, David ^b   Clarke, David J ^b   Kamal, Mujahid ^b   Thorpe, Gerald W ^b   Baria, Karin ^b   Eremin, Oleg ^b,d  

^a UNIVERSITY OF HULL   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LINCOLN   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Breast cancer Docetaxel; Neoadjuvant therapy; Quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DISEASE FREE SURVIVAL; DISTRESS SYNDROME; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; EMOTION; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PERIPHERAL EDEMA; PRIMARY TUMOR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; UNHAPPINESS; VOMITING; ADJUVANT THERAPY; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT COMPLIANCE; RECURRENT DISEASE; SEGMENTAL MASTECTOMY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT COMPLIANCE; QUALITY OF LIFE; RECURRENCE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 79955964554     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-179     Document Type: Article

References (40)

1. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990, 66(6 Suppl):1387-1391.
2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998, 16(1):93-100.
3. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006, 24(12):1940-1949. 10.1200/JCO.2005.02.6187, 16622270.
4. Ellis PA, Smith IE. Primary chemotherapy for early breast cancer. Cancer Treat Rev 1996, 22(6):437-450. 10.1016/S0305-7372(96)90025-0, 9134004.
5. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16(8):2672-2685.
6. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24(13):2019-2027. 10.1200/JCO.2005.04.1665, 16606972.
7. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97(3):188-194. 10.1093/jnci/dji021, 15687361.
8. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19(22):4224-4237.
9. Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 2005, 23(13):2988-2995. 10.1200/JCO.2005.06.156, 15860854.
10. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20(6):1456-1466. 10.1200/JCO.20.6.1456, 11896092.
11. von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, Kaufmann M. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999, 17(7):1999-2005.
12. Walker L, Anderson J, Heys S. Quality of life during primary chemotherapy.: randomised controlled trial of CVAP and docetaxel. Annals of Oncology 1998, 9(Suppl 4):S16.
13. Walker LG, Walker MB, Ogston K, Heys SD, Ah-See AK, Miller ID, Hutcheon AW, Sarkar TK, Eremin O. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer 1999, 80(1-2):262-268. 10.1038/sj.bjc.6690349, 2363003, 10390006.
14. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000, 18(6):1212-1219.
15. Hainsworth JD, Burris HA, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001, 19(15):3500-3505.
16. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004, 15(9):1358-1365. 10.1093/annonc/mdh349, 15319242.
17. Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003, 9(2):686-692.
18. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005, 23(25):5983-5992. 10.1200/JCO.2005.06.232, 16087943.
19. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358(16):1663-1671. 10.1056/NEJMoa0707056, 2743943, 18420499.
20. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997, 15(3):974-986.
21. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990, 62(6):1034-1038. 10.1038/bjc.1990.434, 1971567, 2257209.
22. Anderson J, Walker M, Walker L. The Mood Rating Scale: a brief, acceptable, reliable and valid state measure of normal mood. Psycho-oncology 2000, 9:359.
23. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002, 52(2):69-77. 10.1016/S0022-3999(01)00296-3, 11832252.
24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67(6):361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
25. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977, 35(3):292-298. 10.1038/bjc.1977.42, 2025288, 856236.
26. Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 2001, 12(Suppl 1):S25-29.
27. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000, 18(3):623-631.
28. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002, 11(3):207-221. 10.1023/A:1015276414526, 12074259.
29. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004, 57(9):898-910. 10.1016/j.jclinepi.2004.01.012, 15504633.
30. Chan YH. Biostatistics 103: qualitative data - tests of independence. Singapore Med J 2003, 44(10):498-503.
31. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958, 53:457-481.
32. Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C, Polyzos NP. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev 2009,
33. Aksoy S, Dizdar O, Altundag K. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 359(3):310. author reply 310-311.
34. Schroder CP, de Munck L, Westermann AM, Smit WM, Creemers GJ, de Graaf H, Stouthard JM, van Deijk G, Erjavec Z, van Bochove A, et al. Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel. Eur J Cancer 2011,
35. Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C, Polyzos NP. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev 2010, 36(1):69-74. 10.1016/j.ctrv.2009.10.006, 19945225.
36. Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004, 10(10):3249-3261. 10.1158/1078-0432.CCR-03-0133, 15161677.
37. Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, Banay R, Do KA, Rivera E. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 2006, 24(22):3619-3622. 10.1200/JCO.2005.04.4453, 16877729.
38. Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002, 109(6):1188-1191. 10.1016/S0161-6420(02)00989-2, 12045065.
39. Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 2001, 108(5):994-995. 10.1016/S0161-6420(00)00640-0, 11320034.
40. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002, 3(Suppl 2):S69-74.